Can Management Prove Control of AI Liability Accumulation Risk?

What the Board Should Actually Ask About AI Liability Accumulation

A confident answer in the boardroom is not the same thing as proof of control. AI liability accumulation across lines is exactly the kind of risk where management can sound reassuring while having no actual evidence behind the reassurance. This piece sets out what a board should demand to see, not just hear, before accepting that this risk is under control.

Can management actually prove it has control of AI liability accumulation across lines?

In most organizations today, no, because the underlying data needed to prove it does not yet exist in one place.

Proof of control requires being able to show, on demand, which cedants, lines, and treaties are exposed to which AI vendors, and how that exposure is being tracked and reviewed. Most reinsurers can answer questions about any single line in isolation. Very few can answer the cross-line version of that question with an actual document, register, or dashboard rather than a verbal description of process. That gap between verbal assurance and documented evidence is exactly what a board needs to close before accepting management's answer at face value.

What evidence should a board demand instead of a verbal assurance?

A named owner, a documented exposure register, and evidence of at least one completed test of that register against a realistic scenario.

Verbal assurance costs nothing to give and nothing to receive, which is precisely why it is not sufficient evidence for a risk of this scale. A named owner means there is a specific person accountable if the exposure goes unmanaged, not a diffuse responsibility spread across four functions. A documented register, even an imperfect first version, is evidence that the organization has started converting scattered knowledge into a trackable asset. Who owns AI liability accumulation across underwriting, finance, claims, and risk sets out exactly what that ownership structure should look like in practice.

Why is "we haven't seen a loss yet" not proof of control?

Because the absence of a loss reflects how recently this exposure has been accumulating, not whether it is actually being managed.

Generative-AI-related litigation in the United States grew 978% between 2021 and 2025, which means the claims environment underlying this risk is still young and still accelerating. An organization that has not yet experienced a cross-line AI liability loss may simply not have been tested yet, rather than having built a resilient control. Boards should treat the absence of losses as a reason to test the control proactively, not as evidence that no test is needed.

What questions should board risk committees be asking underwriting leadership?

Specific, evidence-seeking questions that require a document or a number in response, not a description of general awareness.

What should the CUO be able to show in the boardroom?

The CUO should be able to show which AI vendors and models sit behind the organization's largest cedant relationships, and where that data lives.

If the CUO's answer is a description of how underwriters generally think about this risk, rather than a specific register or data source, that is itself useful information for the board. It tells the board the exposure is understood conceptually but not yet tracked operationally, which is a meaningfully different and weaker position.

What should the CRO be able to show in the boardroom?

The CRO should be able to show the current size and refresh status of the cross-line exposure register, plus any material findings from testing it.

Risk Accumulation Monitoring AI Agent can help the CRO produce exactly this kind of concrete, current answer rather than relying on a stale snapshot from an earlier review cycle. A CRO who can show a register that was updated last quarter, with specific findings from a recent tabletop test, is demonstrating something fundamentally different from a CRO who can only describe the topic in general terms.

How does this connect to rating agency and regulatory expectations?

Agencies and regulators increasingly expect a named, tracked exposure category with a documented remediation plan, not a general statement that emerging risks are monitored.

Rating agencies have shown, in the parallel case of silent and non-affirmative cyber exposure, that they respond to specific, named exposure categories with clear remediation timelines far better than to broad statements of awareness. The same expectation is forming around AI liability accumulation, and organizations that get ahead of it with documented evidence will be in a stronger position at the next rating review than those still building their first register. Emerging Risk Monitor AI Agent can help track this exposure alongside other named emerging risks the organization is already reporting on.

What does a credible board reporting cadence look like?

A quarterly update covering register status, any material AI-related claims, and specific progress against a named remediation plan.

A board that receives this level of specificity every quarter is in a fundamentally different position than one receiving a general assurance once a year.

What red flags should tell a board this is not actually under control?

The absence of a named owner, a register that has not been updated since it was first built, and generic status updates that repeat quarter after quarter.

Any one of these signs individually is worth a follow-up question. All three together are a clear signal that this risk is being discussed in governance meetings without being genuinely managed underneath them. Boards that catch this pattern early can redirect management attention before a real cross-line event forces a much more uncomfortable conversation.

What should the board demand happen in the next two quarters?

A completed register, a named owner, and one documented tabletop exercise, each reported back with specific findings rather than a status of "in progress."

This is a realistic, achievable timeline, not an aspirational one, since the underlying data mostly already exists inside underwriting and claims systems. What has been missing is the mandate to assemble it and the discipline to test it, both of which a board can create simply by asking for the evidence directly. The same two-quarter discipline applies on the parallel governance question covered in what the board should demand before tolerating silent technology exposure in legacy wordings.

How should the board factor this risk into its overall risk appetite statement?

AI liability accumulation should be named explicitly in the risk appetite statement, with a stated tolerance, rather than left to be implicitly covered by general liability risk language.

Most existing risk appetite statements were written before AI liability accumulation across lines was a recognized category, so it is rarely named specifically, even in otherwise detailed risk appetite documents. A generic statement about tolerance for liability or emerging risk does not give management a clear target to manage against, since it says nothing about how much cross-line AI concentration the board is actually willing to accept. Naming the risk explicitly, with a stated tolerance such as a maximum acceptable concentration in any single AI vendor across the book, gives management something concrete to manage toward and gives the board something concrete to measure against at each review.

Updating the risk appetite statement is a relatively low-cost governance action compared to the underlying work of building the register itself, and it signals to the rest of the organization that this risk is being treated with the same seriousness as other named categories like natural catastrophe or credit risk.

What should the board expect from external assurance providers on this topic?

Independent verification that the register reflects real, current data, rather than relying solely on management's own internal reporting.

External auditors, actuarial consultants, or specialist reinsurance risk advisors can be asked to independently sample the cross-line register against underlying treaty and claims data, confirming it is accurate and current rather than a document that looks complete but has not actually been maintained. This kind of external assurance is a natural extension of existing audit relationships, not a request for an entirely new advisory engagement, and it gives the board a source of confidence that does not depend entirely on trusting management's self-reporting.

A board that combines a strong internal reporting cadence with periodic external assurance is in the strongest possible position to demonstrate, to regulators, rating agencies, and shareholders alike, that this risk is genuinely being managed rather than simply being discussed.

A board that accepts a confident answer without asking for the register behind it is accepting a story instead of evidence. The organizations that get ahead of AI liability accumulation will be the ones whose boards insisted on seeing the register before the next renewal, not after the first cross-line loss.

Sources

• Risk & Insurance, "Traditional Insurance Leaves Enterprises Exposed as AI Liability Claims Surge"
• Intelligent Insurer, "Lloyd's takes tough stand on 'silent cyber' in new mandate"